Seven Natural Defense Barriers Protect Your Airways from COVID-19 — Including Antimicrobial Peptides | Research

The takeaway

Before the adaptive immune system kicks in, seven constitutive respiratory defense barriers — including antimicrobial peptides like defensins and lactoferrin — work to block SARS-CoV-2 infection.

7 defense barriers
The respiratory tract deploys seven sequential innate defense barriers before adaptive immunity is needed, with antimicrobial peptides forming a key layer

What the researchers found

The review identifies seven constitutive respiratory defense barriers against SARS-CoV-2:

1. Mucus and mucociliary clearance

2. Surfactants (inhibit viral invasion, enhance phagocytosis)

3. Respiratory microbiota (activates immune cells, induces defensins and IgA)

4. Antimicrobial peptides — defensins and lactoferrin (direct antiviral activity, inhibit viral fusion, modulate immunity)

5. Secretory IgA antibodies (inhibit viral cell invasion)

6. Respiratory epithelial cells (restrict receptor access, produce interferons, lactoferrin, defensins)

7. Innate immune cell sensing (triggers adaptive immunity cascade)

Antimicrobial peptides feature prominently in barriers 4 and 6, highlighting their central role in respiratory defense.

Why it matters

Most COVID-19 research focused on adaptive immunity (antibodies and T cells), but innate defenses determine whether the virus ever gains a foothold. Antimicrobial peptides like defensins — which directly kill viruses and block their entry — may explain why some people are naturally more resistant to infection. Understanding these barriers could inform development of prophylactic treatments that boost natural defenses.

The numbers in context

7 defense barriers identified and characterized

How the study worked

Narrative review synthesizing published research on innate respiratory defense mechanisms against SARS-CoV-2, organized as seven sequential barriers from the airway surface to innate immune cell activation.

Who was studied

Review article (no study population)

What this study cannot tell us

This is a narrative review published in 2021 when understanding of SARS-CoV-2 was still evolving. Some mechanisms described may have been revised as new data emerged. The relative importance of each barrier in determining clinical outcomes is not quantified. Individual variation in barrier effectiveness — which likely determines susceptibility — is discussed qualitatively but not systematically.

How to read the evidence

This is a narrative review synthesizing existing knowledge about innate respiratory defenses in the context of SARS-CoV-2. It provides a useful conceptual framework but no original experimental data.

When this study was published

Published in 2021 during the COVID-19 pandemic, this review captured early understanding of how innate defenses interact with SARS-CoV-2. Some aspects may have been updated by subsequent research.

The bigger picture

The COVID-19 pandemic highlighted gaps in understanding innate respiratory immunity. Antimicrobial peptides have long been studied in skin and gut immunity, but their role in airway defense against respiratory viruses received less attention. This review contextualizes defensins and lactoferrin within the broader architecture of respiratory defense, suggesting that strategies to enhance antimicrobial peptide production could improve pandemic preparedness.

Questions still open

Can therapeutic supplementation with defensins or lactoferrin peptides enhance respiratory defense against SARS-CoV-2 or future pandemic viruses?
Which of the seven barriers is most variable between individuals, and does this explain differences in COVID-19 susceptibility?
Could inhaled antimicrobial peptides serve as a prophylactic treatment during viral outbreaks?

Common questions

What are defensins and how do they fight viruses?

Defensins are small antimicrobial peptides produced by cells lining the airways and by immune cells. They fight viruses in multiple ways: directly killing or inactivating viral particles, blocking viruses from fusing with host cells, and activating immune cells to mount a stronger response. They are part of the body's first line of defense, working before antibodies are produced.

Can you boost these natural defenses to protect against respiratory infections?

Possibly. Some research suggests that adequate nutrition (especially zinc, vitamin D, and certain amino acids), a healthy respiratory microbiome, and avoiding factors that damage airway defenses (like smoking) can help maintain these barriers. Inhaled antimicrobial peptides are also being explored as potential prophylactic treatments, though this remains experimental.

Read the original research

The seven constitutive respiratory defense barriers against SARS-CoV-2 infection.

Revista da Sociedade Brasileira de Medicina Tropical, 54, e04612021

View on PubMed ↗Publisher’s paper ↗

Citation

Tosta, Eduardo. (2021). The seven constitutive respiratory defense barriers against SARS-CoV-2 infection.. Revista da Sociedade Brasileira de Medicina Tropical, 54, e04612021. https://doi.org/10.1590/0037-8682-0461-2021